Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: Analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA Study)

Drugs and Aging

Volumn 28, Issue 9, 2011, Pages 681-692

  Nakaya, Noriaki ^a   Mizuno, Kyoichi ^b   Ohashi, Yasuo ^c   Teramoto, Tamio ^d   Yokoyama, Shinji ^e   Hirahara, Katsumi ^f   Mizutani, Masahiro ^g   Nakamura, Haruo ^h  

^a Nakaya Clinic   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^f Hirahara Internal Clinic   (Japan)

^g Asahiyama Internal Clinic   (Japan)

^h Mitsukoshi Health and Welfare Foundation   (Japan)

Author keywords

Cardiovascular disorders; HMG CoA reductase inhibitors; Hypercholesterolaemia; Pravastatin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPANESE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEOPLASM; OBESITY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK REDUCTION; SEX DIFFERENCE; SIDE EFFECT; STROKE; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRAVASTATIN; RISK FACTORS; STROKE;

EID: 80052851569     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11595620-000000000-00000     Document Type: Article

References (38)

1. Health and Welfare Statistics Association. Statistical abstracts on health and welfare in Japan 2006. Tokyo: Health and Welfare Statistics Association, 2007
2. Berger K, Schulte H, Stögbauer F, et al. Incidence and risk factors for stroke in an occupational cohort: the PROCAM study. Prospective Cardiovascular Muenster study. Stroke 1998 Aug; 29 (8): 1562-6 (Pubitemid 28365574)
3. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992 Dec 14; 70 (19): 3H-9H (Pubitemid 23006056)
4. Castelli WP, Garrison RJ, Dawber TR, et al. The filter cigarette and coronary heart disease: the Framingham study. Lancet 1981 Jul 18; 2 (8238): 109-13 (Pubitemid 11074961)
5. Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension: the Framingham study. Circulation 1980 Jun; 61 (6): 1179-82 (Pubitemid 10116256)
6. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979 Jan; 59 (1): 8-13 (Pubitemid 9082394)
7. Kannel WB, Wilson PW, Nam BH, et al. Risk stratification of obesity as a coronary risk factor. Am J Cardiol 2002 Oct 1; 90 (7): 697-701 (Pubitemid 35279387)
8. Kubo M, Kiyohara Y, Kato I, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003 Oct; 34 (10): 2349-54 (Pubitemid 37221940)
9. Nakamura Y, Yamamoto T, Okamura T, et al. Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980-1994. Circ J 2006 Aug; 70 (8): 960-4 (Pubitemid 44161730)
10. Wakugami K, Iseki K, Kimura Y, et al. Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan. Jpn Circ J 1998 Jan; 62 (1): 7-14
11. Wilson PW, Garrison RJ, Castelli WP, et al. Prevalence of coronary heart disease in the Framingham Offspring study: role of lipoprotein cholesterols. Am J Cardiol 1980 Oct; 46 (4): 649-54 (Pubitemid 10009820)
12. King RB. Quality of life after stroke. Stroke 1996 Sep; 27 (9): 1467-72 (Pubitemid 26295890)
13. Westin L, Carlsson R, Israelsson B, et al. Quality of life in patients with ischaemic heart disease: a prospective controlled study. J Intern Med 1997 Sep; 242 (3): 239-47 (Pubitemid 27400437)
14. Hackett ML, Yapa C, Parag V, et al. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005 Jun; 36 (6): 1330-40 (Pubitemid 40798764)
15. Spertus JA, McDonell M, Woodman CL, et al. Association between depression and worse disease-specific functional status in outpatients with coronary artery disease. Am Heart J 2000 Jul; 140 (1): 105-10 (Pubitemid 30471248)
16. Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, et al. Poststroke dementia: clinical features and risk factors. Stroke 2000 Jul; 31 (7): 1494-501 (Pubitemid 30437493)
17. Hellénius ML, de Faire U, Berglund B, et al. Diet and exercise are equally effective in reducing risk for cardiovascular disease: results of a randomized controlled study in men with slightly to moderately raised cardiovascular risk factors. Atherosclerosis 1993 Oct; 103 (1): 81-91 (Pubitemid 23313142)
18. Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000 Jul 6; 343 (1): 16-22 (Pubitemid 30447987)
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid- Lowering Treatment to Prevent HeartAttack Trial (ALLHATLLT). JAMA 2002 Dec 18; 288 (23): 2998-3007
20. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 2004 Aug 21-27; 364 (9435): 685-96 (Pubitemid 39140624)
21. Collins R, Armitage J, Parish S, et al. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004 Mar 6; 363 (9411): 757-67
22. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex- CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 May 27; 279 (20): 1615-22 (Pubitemid 28248586)
23. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339 (19): 1349-57
24. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 Oct 3; 335 (14): 1001-9 (Pubitemid 26338729)
25. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344 (8934): 1383-9
26. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5; 361 (9364): 1149-58 (Pubitemid 36398384)
27. Shepherd J, BlauwGJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23; 360 (9346): 1623-30 (Pubitemid 35379733)
28. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004 Sep; 68 (9): 860-7
29. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 2006 Sep 30; 368 (9542): 1155-63 (Pubitemid 44444932)
30. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study: a novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992 Aug; 1 (2): 113-9
31. National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1993; 89 (3): 1333-445
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 Jun; 18 (6): 499-502
33. Tanaka Y, Matsuyama Y, Ohashi Y. Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Stat Med 2008 May 10; 27 (10): 1718-33 (Pubitemid 351566093)
34. Ishikawa T, Mizuno K, Nakaya N, et al., for the MEGA Study Group. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circ J 2008 Oct; 72: 1576-82
35. Uchiyama S, Nakaya N, Mizuno K, et al., for the MEGA Study Group. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA study, a large randomized controlled trial. J Neurol Sci 2009 Sep 15; 284: 72-6
36. Qiu H, Depre C, Vatner SF, et al. Sex differences in myocardial infarction and rupture. J Mol Cell Cardiol 2007 Nov; 43 (5): 532-4 (Pubitemid 47615051)
37. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001 May 15; 134 (10): 931-40 (Pubitemid 32466232)
38. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002 Apr 20; 359 (9315): 1379-87